Weismüller T.J., Strassburg C.P., Trivedi P.J., Hirschfield G.M., Trivedi P.J., Bergquist A., Said K., Imam M., Lazaridis K.N., Juran B.D., Cheung A., Lindor K.D., Weismüller T.J., Lenzen H., Manns M.P., Ponsioen C.Y., Beuers U., Holm K., Naess S., Karlsen T.H., Schrumpf E., Boberg K.M., Gotthardt D., Rupp C., Färkkilä M.A., Jokelainen K., Marschall H.-U., Benito de Valle M., Thorburn D., Saffioti F., Weersma R.K., Fevery J., Mueller T., Chazouillères O., Schulze K., Schramm C., Almer S., Pereira S.P., Levy C., Mason A., Bowlus C.L., Floreani A., Halilbasic E., Trauner M., Yimam K.K., Milkiewicz P., Milkiewicz P., Huynh D.K., Pares A., Manser C.N., Dalekos G.N., Eksteen B., Invernizzi P., Berg C.P., Kirchner G.I., Sarrazin C., Zimmer V., Fabris L., Braun F., Marzioni M., Schramm C., Chapman R.W., Chapman R.W., Lindor K.D., Imam M., Lindor K.D., Naess S., Karlsen T.H., Schrumpf E., Boberg K.M., Hansen B.E., Hansen B.E., Hansen B.E., on behalf of the, International PSC Study Group (2017)
Background & Aims Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary disorder associated with inflammatory bowel disease (IBD). We aimed to estimate the risk of disease progression based on distinct clinical ...